

DirectConnect

Inside Yale Cancer Center

March 21, 2014

Announcements

Yale Cancer Center/Smilow Cancer Hospital Elected into



National
Comprehensive
Cancer
Network®

National Comprehensive Cancer Network
Your Best Resource in the Fight Against Cancer®

NCCN

I am very pleased to announce that Yale Cancer Center/Smilow Cancer Hospital was elected in to the National Comprehensive Cancer Network, along with Mayo Clinic, at their annual meeting on Friday. NCCN defines quality cancer care and sets national standards for all practices and we're delighted to be part of this outstanding organization. There are now 25 members of NCCN.

"The election of Yale Cancer Center into institutional membership is a true testament to the growth and impact of NCCN," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "The expertise of this academic cancer center's faculty enhances the collaboration of NCCN Member Institutions as we further the mission of NCCN to improve the lives of patients with cancer in the United States and worldwide."

[Read More >>](#)

Kerin Adelson Named Chief Quality Officer for Smilow

Kerin Adelson, MD will join Smilow Cancer Hospital as Chief Quality Officer this spring. In this new role, Kerin will oversee patient safety and quality initiatives at Smilow and at the Care Centers; advance clinical informatics, including EPIC and Care Pathways; and develop a robust research program in quality cancer care.



Dr. Adelson is a medical oncologist specializing in breast cancer

from the desk of

Thomas J. Lynch, Jr., MD

Director, Yale Cancer Center

Physician-in-Chief Smilow Cancer

Hospital at Yale-New Haven



SMILOW CANCER HOSPITAL
AT YALE-NEW HAVEN

Yale CANCER
CENTER

A Comprehensive Cancer Center Designated
by the National Cancer Institute

Recent News

Read recent articles featuring experts from Yale Cancer Center.
[News Center >>](#)

LATEST ARTICLES:



National
Comprehensive
Cancer
Network®

YCC/Smilow named NCCN
Member Institution

MARCH 17, 2014

[Read More >>](#)



Ellen Matloff on Oophorectomy
Timing for BRCA Carriers

MARCH 10, 2014

[Read More >>](#)

and currently practices at Mount Sinai, where she is the Director of Ambulatory Quality for the Mount Sinai Cancer Network. She is a graduate of the University of California and received her Medical Degree from Yale School of Medicine. Dr. Adelson did her residency and internship at Mount Sinai and a fellowship in Clinical Quality at the Greater New York Hospital Association.

Notables

The American Academy of Orthopaedic Surgeons (AAOS) today presented the 2014 William W. Tipton Leadership Award to **Gary E. Friedlaender, MD**. The Tipton Leadership Award recognizes Academy members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients, and/or the American public. [Learn More >>](#)

Leah Ferrucci, PhD received the **Best Poster Award** at the **American Society of Preventive Oncology** meeting for her poster, "Ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma."

Dr. Laura Morrison and **Dr. Andrew Putnam** presented at the **Annual Assembly of the American Academy of Hospice and Palliative Medicine** last week on "Reducing the Need for Narcotics: The Role of the Neurointerventional Radiologist in Pain Management."

Research in the News

Breaking new ground: Yale team implants human innate



immune cells in mice

Overcoming a major limitation to the study of the origins and progress of human disease, Yale researchers report that they have transplanted human innate immune cells into mouse models, which resulted in human immune responses. This groundbreaking study has reproduced human immune function at a level not seen previously, and could significantly improve the translation of knowledge gained from mouse studies into humans. The study is published online in *Nature Biotechnology*.

The Yale team was able to overcome this obstacle by combining human versions of four genes encoding cytokines - proteins that support immune cell development - when transplanting a human immune system into the mouse. These cytokines support the development and functions of many elements of the innate



Blumenthal, DeLauro:
E-hookahs marketed to children
MARCH 10, 2014

[Read More >>](#)

Follow Yale Cancer Center on Twitter

Follow us on 

LATEST TWEETS:

 RT @Yale: Breaking new ground: Yale team implants human innate immune cells in mice <http://bit.ly/1eKug6O>

 @NCCNMeetings announced today that it has elected @YaleCancer/@YNHH to join its alliance of leading cancer centers. <http://bit.ly/1eKXOkT>

 Tune in to @YaleCancer Answers at 6 PM @WNPR with Dr. Rossitza Lazova on the diagnosis of skin lesions and identifying skin cancers.

 MT @AneesChagpar: @YaleCancer Breast fellow, Prathima Kanumuri, takes on multifocal and multicentric #breastcancer at #SSO2014

 Phase II trial to assess sipuleucel-T with enzalutamide in men with metastatic castrate resistant #prostatecancer <http://bit.ly/OolrsV>

 Congrats to Leah Ferrucci winner for best poster at Amer. Soc. of Prev. Onc. for study on UV radiation behaviors of #skincancer survivors.

Join Yale Cancer Center

immune system.

[Read More >>](#)

New prostate cancer treatment convenient, less expensive, but may be riskier

A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers - a higher rate of urinary complications.

The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer treatment that delivers a greater dose of radiation per treatment than IMRT. As a result, patients receiving SBRT can complete an entire course of treatment in one to two weeks, compared to seven to nine weeks for IMRT. There have been few studies comparing the costs of these treatments, and their toxicity.

This new study - published in the March 10 *Journal of Clinical Oncology* by researchers at the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale Cancer Center- compared IMRT to SBRT in a national sample of 4,005 Medicare patients age 66 and older receiving prostate cancer treatment. Participants received either SBRT or IMRT as a primary treatment for prostate cancer during 2008 to 2011.

[Read More >>](#)

Closer to Free

Quinnipiac Bank in Hamden recently demonstrated some creative philanthropy that benefited **Closer to Free** as well as **St. Jude Children's Research Hospital in Memphis, TN**. During the 2013 holiday season, the bank participated in a charitable program for St. Jude's by making a contribution. In return they received a large number of plush bears and puppies. The bank administration sold the toys to their



on Facebook

Like us on Facebook 

LATEST POSTS:

Meet Alberto, a throat cancer survivor who recently shared his story with other patients at Smilow Cancer Hospital's Head and Neck Cancer Program.



[Read More >>](#)

Yale Cancer Center and Smilow Cancer Hospital will sponsor a free lung cancer screening for those at high-risk for the disease on Saturday, April 12. Call 1-800-700-6543 to learn more or to register for the screening



[Read More >>](#)

Yale Cancer Center researchers have published a review showing that Stereotactic body radiotherapy (SBRT), a newer treatment for prostate cancer that delivers a greater dose of radiation than the standard intensity modulated radiation therapy (IMRT) may be riskier for patients.

customers, intending to send the additional funds raised to St. Jude's. A bank customer suggested donating the proceeds to **Closer to Free**. This past week, Bank President Mark Candido and his administrators presented a check to **Closer to Free**. Michael Carrano, Branch Manager and Jaime McElhill, Executive Assistant are pictured here next to Mr. Candido. The program was so successful, the bank sold out of toys, and plans on contributing more to St. Jude's next year, and subsequently to **Closer to Free**.

Every gift, large or small, has a positive impact on the patients and their families, researchers and care providers - all of us who make up the **Closer to Free** community. Information about making a donation or organizing an event is available on the Give **Closer to Free** [website](#) or by contacting [Susan Frankenbach](#). Don't forget to "like" us on [Facebook](#)!

Funding and Award Opportunities

Alex's Lemonade Stand Foundation

We are pleased to announce that grant guidelines and applications are now open for submission in the following categories:

Bridge Grants Cycle

This grant is designed to sustain research projects falling between the end of funding by the National Institutes of Health (NIH) R or P Award and the beginning of a competitively renewed NIH Award. Renewal applications which scored less than or equal to the 35th percentile but were not funded will be eligible for Bridge Grants. Applicants must have a plan to resubmit for NIH funding. This is a one year award of \$100,000 in total costs.

Application Deadline: April 10, 2014

Springboard Grants Cycle

This grant supports new National Institutes of Health (NIH) R01 or P01 research applications which were scored less than or equal to the 25th percentile but were not funded. Applicants must have a plan to resubmit for NIH funding. This is a one year award of \$100,000 in total costs.

Application Deadline: April 10, 2014


'A' Awards

NEW in 2014, the award amount has increased to \$150,000 per year for three years! Designed for early career scientists with an original project who can demonstrate outstanding mentorship and have a strong future commitment to pediatric cancer investigation. This award totals \$450,000 over three years and is open to MD, MD/PhD and PhD candidates.

Application Deadline: May 23, 2014

Reach Awards

Our Reach Awards are designed to move hypothesis-driven research toward the clinic. The goal of this award is to support selected "late translational" studies needed to ultimately initiate a clinical trial. A successful application will identify an unmet clinical need relevant to the care of pediatric cancer patients and describe how the proposed project will allow for the pre-clinical research to



[Read More >>](#)

Events

March 21; 12:00 PM

YCC Research in Progress Meeting

NP4-101A

Update on Clinical Trials in GI Oncology

Howard Hochster, MD

[Learn More >>](#)

March 21; 1:00PM

YCC Developmental Therapeutics Research Program Meeting

SHM I-116

Sodium/iodide symporter (NIS)-mediated radioiodide therapy: from thyroid to breast cancer
Maysa Abu-Khalaf, MBBS, MD, and Nancy Carrasco, MD

[Learn More >> PDF](#)

March 23; 6:00PM

Yale Cancer Center Answers WNPR

Screening Tools for Lung Cancer
Gaetene Michaud, MD, MSc

[Learn More >>](#)

March 25; 9:30AM

Pathology Research in Progress Talks

TAC N-107

TBA

Andrew Sawyer, PhD and Paul Cao, PhD

[Learn More >>](#)

March 25; 12:00PM

Yale Cancer Center Grand Rounds/Blanche Tullman Lecture

Park Street Auditorium

New Insights into Therapeutic Targets in Multiple Myeloma
Kenneth Anderson, MD

[Learn More >> PDF](#)

March 26; 11:00AM

be translated to the clinic while keeping broader clinical testing and implementation in view. Maximum of \$250,000 in total costs awarded over two years.

Application Deadline: May 30, 2014

[Learn More >>](#)

Lung Cancer Research Foundation Grants

Support research on innovative strategies for better treatments, screening, and prevention of all cancers of the lung. These awards are designed to provide critical seed support for cutting-edge scientific research on all lung cancers and will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes. Up to \$50,000 for 1 year.

Application Deadline: June 16, 2014

[Learn More >>](#)

Employee Profile: Jan Shanley

The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess.

To suggest someone to be profiled, please contact [Emily Fenton](#).

Jan Shanley has been a part of the Early Drug Development Program (also known as the Phase I Clinical Trials Program) as an Infusion Nurse from the beginning. In just under a year, under the direction of Dr. Joseph Paul Eder, the program has grown to include 10 Phase I trials. Jan is responsible for administering the investigational drugs to patients and monitoring their care. Before working with the Phase I Program, Jan was a nurse in medical oncology for seven years.

Before a patient can start any clinical trial, they must meet certain eligibility criteria. Jan plays a vital role in the screening as well as in the treatment of these patients. "You can't help but develop relationships with these patients that you are seeing sometimes almost daily. It is awesome to see them complete the trial and



YCC Radiobiology and Radiotherapy Research Program

SHM I-304

Regulators and Mechanisms of Tumor Initiation and Progression
Narendra Wajapeyee, PhD

[Learn More >> PDF](#)

March 26; 1:00PM YCC Genetics and Genomics Research Program

Giarman Room, SHM B-201

Epigenetic Regulation in Pluripotent Stem Cells and its Implications in Cancer

Andrew Xiao, PhD

[Learn More >> PDF](#)

March 28; 12:00PM Canceled: YCC Research in Progress Meeting

NP4-101A

[Learn More >>](#)

March 30; 6:00PM Yale Cancer Center Answers

WNPR

Options for Fertility Preservation in Patients with Cancer

Emre Seli, MD

[Learn More >>](#)

April 1; 9:30AM Pathology Research in Progress Talks

TAC N-107

"Role of the Immune System in EGFR Mutant Lung Cancer" and
"Biomedical Image Classification Using Random Convolutional Networks"

Masayuki Tsuneki, DMD, PhD

[Learn More >>](#)

April 1; 12:00PM Yale Cancer Center Grand Rounds

Park Street Auditorium

TBA

[Learn More >>](#)

April 3; 11:00AM Therapeutic Radiology Seminar

SHM I-116

Next Generation Personalized Medicine Strategies May Lead to Improved Patient Outcomes

Robert Beckman, MD, FAAP

[Learn More >> PDF](#)

April 3; 12:30PM

come in for follow-up scans and see that they are disease free and doing well," said Jan. "These trials are groundbreaking and it's amazing to be a part of such a robust program and team."

Jan sees herself as on the frontline of getting these research drugs to patients. There are people working behind the scenes, the researchers, data managers, etc. that make what she does possible and help patients live longer, and in some cases, live disease free for years. She commented that there is always something new happening and she loves working with the patients.

Karen Thimble, RN, MSN, APSM for the Smilow 8 Infusion and Phase I Program, and Jan's supervisor, commented, "Jan always keeps the patients first in the delivery of her safe, efficient care. She is concerned about how they get to treatment, how their families are affected and how they are feeling outside of the hospital. She wants them to lead as normal a life as they can, under the circumstances. She is wonderful."

Recent Publications

Development and function of human innate immune cells in a humanized mouse model.

Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, Manz MG, Flavell RA.

Nat Biotechnol. 2014 Mar 16.

[Read More >>](#)

Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.

Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.

Antiviral Res. 2014 Mar 12.

[Read More >>](#)

Immunotherapy applications of carbon nanotubes: from design to safe applications.

Fadel TR, Fahmy TM.

Trends Biotechnol. 2014 Mar 11.

[Read More >>](#)

Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers.

Shi W, Balazs B, Györfy B, Jiang T, Symmans WF, Hatzis C, Pusztai L.

Breast Cancer Res Treat. 2014 Mar 12.

Pharmacology Special Seminar

Brady Auditorium, B-131

Pin1-Catalyzed Conformational Regulation after

Phosphorylation: Novel Signaling Mechanism and Drug Target in Cancer and Alzheimer's?

Kun Ping Lu, MD, PhD

[Learn More >>](#)

April 4; 12:00PM YCC Research in Progress Meeting

NP4-101A

TBA

Nataliya Uboha, MD, PhD and

Roxanne Wadia, MD

[Learn More >>](#)

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

Employment Opportunities

Success in any clinical research endeavor, but especially in cancer research, requires the most qualified, dedicated staff, committed to excellence and the mission of Yale Cancer Center. The combination of education, oncology research experience, and exceptional nursing skills is enormously difficult to find. Your participation, as knowledgeable colleagues, is invaluable at this time.

Should you know individuals with outstanding clinical research nursing experience, and who are ready to join our team, please direct resumes to [Sandra Greer](#), Sr. Staffing and Career Development Representative or call (203) 432-5822. All referrals will be held in strictest confidence.

Submissions

[Read More >>](#)

Transoral Robotic Surgery: A Population-Level Analysis.

Chen MM, Roman SA, Kraus DH, Sosa JA, Judson BL.
Otolaryngol Head Neck Surg. 2014 Mar 11.

[Read More >>](#)

Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity.

Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP.
J Clin Oncol. 2014 Mar 10.

[Read More >>](#)

A penalized robust method for identifying gene-environment interactions.

Shi X, Liu J, Huang J, Zhou Y, Xie Y, Ma S.
Genet Epidemiol. 2014 Apr;38(3):220-30.

[Read More >>](#)

Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue.

Aktas B, Sun H, Yao H, Shi W, Hubbard R, Zhang Y, Jiang T, Ononye SN, Wali VB, Pusztai L, Symmans WF, Hatzis C.
Mol Oncol. 2014 Feb 17.

[Read More >>](#)

Reverse Phase Protein Array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.

Sewell A, Brown BT, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG.
Clin Cancer Res. 2014 Mar 5.

[Read More >>](#)

Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer.

Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP.
J Natl Cancer Inst. 2014 Mar 5.

[Read More >>](#)

Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers.

Tilburt JC, Kelley S, DeCourtney CA, Humeniuk KM, Latini J, Kim SP.

Int J Circumpolar Health. 2014 Feb 27;73:23637.

[Read More >>](#)

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu